Congressionally Directed Medical Research Programs (CDMRP) DoD Funding Opportunities Lung Cancer Research Programs - July Deadline

How to Apply: 

The FY22 Defense Appropriations Act is anticipated to provide funding for the LCRP to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s (DHP) Research, Development, Test and Evaluation appropriation.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).


The FY22 LCRP funding opportunity announcements for the following award mechanisms are posted on the website. 


Applications submitted to the FY22 LCRP must address one or more of the following Areas of Emphasis:


  • Identify innovative strategies for the prevention of the occurrence of lung cancer.
  • Identify innovative strategies for the screening and early detection of lung cancer.
  • Understand the molecular mechanisms of initiation and progression to lung cancer.
  • Understand contributors to lung cancer development other than tobacco.
  • Identify innovative strategies for the treatment of lung cancer.
  • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
  • Develop or optimize biomarkers to assist with therapeutic decision-making
  • Understand mechanisms of resistance to treatment (primary and secondary)
  • Identify innovative strategies for comprehensive lung cancer care (clinical management/surveillance/symptom management/palliative care).
  • Understand factors and/or develop implementation strategies to address health disparities in lung cancer.


Relevance to Military Health:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service Members, Veterans, and their families.  Relevance to military health will be considered in determining relevance to the mission of the DHP and FY22 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:


  • Use of military of Veteran populations, biospecimens, data/databases, or programs in the proposed research.
  • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators.
  • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population.
  • Explanation of how the project addresses an aspect of lung cancer that has a direct relevance to military Service Members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco.


Funding Opportunities-FY22 LCRP, Congressionally Directed Medical Research Programs (CDMRP) (


Clinical Translational Research Partnership Award – Letter of Intent due July 13, 2022

Investigators at or above the level of Assistant Professor (or equivalent)

Clinician must be an M.D., M/D//Ph.D., or equivalent with clinical duties and/or responsibilities

  • ·        Supports translational studies that include an interventional clinical trial.
  • ·        This mechanism is intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.

○       One partner is strongly encouraged to be from either a military treatment facility or a U.S. Department of Veterans Affairs medical center.

  • ·        Non-traditional partnerships are encouraged.
    • ·        Preliminary lung cancer relevant data are required.
    • ·        Relevance to military health is strongly encouraged.
    • ·        Patient research advocate involvement is encouraged.
      • ·        Maximum combined funding of $1,200,000 for direct costs (plus indirect costs).
      • ·        Maximum period of performance should not exceed 3 years.


A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the website.  The application package containing the required forms for each award mechanism will also be found on  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 


For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (


Point of Contact:

CDMRP Help Desk


Please contact Jill Sherman, International Research Facilitator, at for more information.


External Deadline: 
Wednesday, July 13, 2022
Funding Source: 
Funding Level: